<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37289322</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy's disease.</ArticleTitle><Pagination><StartPage>4478</StartPage><EndPage>4486</EndPage><MedlinePgn>4478-4486</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11802-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To what extent retinal atrophy in neurodegenerative diseases reflects the severity and/or the chronicity of brain pathology or is a local independent phenomenon remains to be clarified. Moreover, whether retinal atrophy has a clinical (diagnostic and prognostic) value in these diseases remains unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To add light on the pathological significance and clinical value of retinal atrophy in patients with amyotrophic lateral sclerosis (ALS) and Kennedy's disease (KD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-five ALS, thirty-seven KD, and forty-nine age-matched healthy controls (HC) were included in a one-year longitudinal study. Spectrum-domain optical coherence tomography (OCT) was performed at study entry (T0) and after 12&#xa0;months (T1). Disease duration and functional rating scale (FRS) for ALS and KD patients were correlated to retinal thicknesses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to HC, peripapillary retinal nerve fiber layer (pRNFL) thickness was significantly thinner in both ALS (p&#x2009;=&#x2009;0.034) and KD (p&#x2009;=&#x2009;0.003). pRNFL was thinner in KD compared to ALS, but the difference was not significant. In KD, pRNFL atrophy significantly correlated with both disease severity (r&#x2009;=&#x2009;0.296, p&#x2009;=&#x2009;0.035) and disease duration (r&#x2009;=&#x2009;-&#x2009;0.308, p&#x2009;=&#x2009;0.013) while no significant correlation was found in ALS (disease severity: r&#x2009;=&#x2009;0.147, p&#x2009;=&#x2009;0.238; disease duration: r&#x2009;=&#x2009;-&#x2009;0.093, p&#x2009;=&#x2009;0.459). During the follow-up, pRNFL thickness remained stable in KD while significantly decreased in ALS (p&#x2009;=&#x2009;0.043).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study provides evidence of retinal atrophy in both ALS and KD and suggests that retinal thinning is a primary local phenomenon in motoneuron diseases. The clinical value of pRNFL atrophy in KD is worthy of further investigation.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miscioscia</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7465-6246</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, DNS, School of Medicine, University of Padua, Padua, Italy. alessandro.miscioscia@phd.unipd.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multiple Sclerosis Centre of the Veneto Region (CeSMuV), Neurology Clinic, University Hospital of Padua, Via Giustiniani, 5, 35128, Padua, Italy. alessandro.miscioscia@phd.unipd.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puthenparampil</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, DNS, School of Medicine, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multiple Sclerosis Centre of the Veneto Region (CeSMuV), Neurology Clinic, University Hospital of Padua, Via Giustiniani, 5, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasi</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, DNS, School of Medicine, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Center, Neurology Clinic, University Hospital of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Centre of the Veneto Region (CeSMuV), Neurology Clinic, University Hospital of Padua, Via Giustiniani, 5, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Centre of the Veneto Region (CeSMuV), Neurology Clinic, University Hospital of Padua, Via Giustiniani, 5, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorar&#xf9;</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, DNS, School of Medicine, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Center, Neurology Clinic, University Hospital of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, DNS, School of Medicine, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multiple Sclerosis Centre of the Veneto Region (CeSMuV), Neurology Clinic, University Hospital of Padua, Via Giustiniani, 5, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012162" MajorTopicYN="Y">Retinal Degeneration</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Kennedy&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Motoneuron disease</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Optical coherence tomography</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>11</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37289322</ArticleId><ArticleId IdType="pmc">PMC10421755</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11802-2</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11802-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlqvist JR, Fornander F, de Stricker BJ, et al. Disease progression and outcome measures in spinobulbar muscular atrophy. Ann Neurol. 2018;84:754&#x2013;765. doi: 10.1002/ana.25345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25345</ArticleId><ArticleId IdType="pubmed">30255951</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;bers A, M&#xfc;ller HP, Dreyhaupt J, et al. Retinal involvement in amyotrophic lateral sclerosis: a study with optical coherence tomography and diffusion tensor imaging. J Neural Transm. 2016;123:281&#x2013;287. doi: 10.1007/s00702-015-1483-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-015-1483-4</ArticleId><ArticleId IdType="pubmed">26582428</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohani M, Meysamie A, Zamani B, et al. Reduced retinal nerve fiber layer (RNFL) thickness in ALS patients: a window to disease progression. J Neurol. 2018;265:1557&#x2013;1562. doi: 10.1007/s00415-018-8863-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8863-2</ArticleId><ArticleId IdType="pubmed">29713825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee N, McBurney-Lin S, Kuo A, et al. Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease. PLoS One. 2017;12:e0185242. doi: 10.1371/journal.pone.0185242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0185242</ArticleId><ArticleId IdType="pmc">PMC5612691</ArticleId><ArticleId IdType="pubmed">28945811</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9:921&#x2013;932. doi: 10.1016/S1474-4422(10)70168-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70168-X</ArticleId><ArticleId IdType="pubmed">20723847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotirchos ES, Gonzalez Caldito N, Filippatou A, et al. Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy. Ann Neurol. 2020;87:885&#x2013;896. doi: 10.1002/ana.25738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25738</ArticleId><ArticleId IdType="pmc">PMC8682917</ArticleId><ArticleId IdType="pubmed">32285484</ArticleId></ArticleIdList></Reference><Reference><Citation>Miscioscia A, Puthenparampil M, Miante S, et al. Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis. J Neurol. 2022;269:5436&#x2013;5442. doi: 10.1007/s00415-022-11183-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11183-y</ArticleId><ArticleId IdType="pmc">PMC9467948</ArticleId><ArticleId IdType="pubmed">35648233</ArticleId></ArticleIdList></Reference><Reference><Citation>Song A, Johnson N, Ayala A, Thompson AC. Optical coherence tomography in patients with Alzheimer&#x2019;s disease: what can it tell us? Eye Brain. 2021;13:1&#x2013;20. doi: 10.2147/EB.S235238.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/EB.S235238</ArticleId><ArticleId IdType="pmc">PMC7802785</ArticleId><ArticleId IdType="pubmed">33447120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha LP, Almeida ALM, Costa-Cunha LVF, et al. The role of optical coherence tomography in Alzheimer&#x2019;s disease. Int J Retina Vitr. 2016;2:24. doi: 10.1186/s40942-016-0049-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40942-016-0049-4</ArticleId><ArticleId IdType="pmc">PMC5088456</ArticleId><ArticleId IdType="pubmed">27847642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vergara AJ, Restrepo-Jimenez P, Pelak VS. Optical coherence tomography in mild cognitive impairment: a systematic review and meta-analysis. Front Neurol. 2020 doi: 10.3389/fneur.2020.578698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.578698</ArticleId><ArticleId IdType="pmc">PMC7596384</ArticleId><ArticleId IdType="pubmed">33178120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L-J, Xu L-L, Mao C, et al. Progressive changes in the retinal structure of patients with Parkinson&#x2019;s disease. J Parkinsons Dis. 2018;8:85&#x2013;92. doi: 10.3233/JPD-171184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-171184</ArticleId><ArticleId IdType="pubmed">29480221</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailankody P, Battu R, Khanna A, et al. Optical coherence tomography as a tool to evaluate retinal changes in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2015;21:1164&#x2013;1169. doi: 10.1016/j.parkreldis.2015.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.08.002</ArticleId><ArticleId IdType="pubmed">26297381</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrysou A, Jansonius NM, van Laar T. Retinal layers in Parkinson&#x2019;s disease: a meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism Relat Disord. 2019;64:40&#x2013;49. doi: 10.1016/j.parkreldis.2019.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2019.04.023</ArticleId><ArticleId IdType="pubmed">31054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Breza M, Koutsis G. Kennedy&#x2019;s disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease. J Neurol. 2019;266:565&#x2013;573. doi: 10.1007/s00415-018-8968-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8968-7</ArticleId><ArticleId IdType="pubmed">30006721</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa E, Sorar&#xf9; G, Kleinbub JR, et al. Theory of mind, empathy and neuropsychological functioning in X-linked spinal and bulbar muscular atrophy: a controlled study of 20 patients. J Neurol. 2015;262:394&#x2013;401. doi: 10.1007/s00415-014-7567-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7567-5</ArticleId><ArticleId IdType="pubmed">25408365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord. 2015;25:554&#x2013;562. doi: 10.1016/j.nmd.2015.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2015.03.008</ArticleId><ArticleId IdType="pmc">PMC5608513</ArticleId><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86:2303&#x2013;2309. doi: 10.1212/WNL.0000000000002774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002774</ArticleId><ArticleId IdType="pmc">PMC4909557</ArticleId><ArticleId IdType="pubmed">27225223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7:e34823. doi: 10.1371/journal.pone.0034823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034823</ArticleId><ArticleId IdType="pmc">PMC3334941</ArticleId><ArticleId IdType="pubmed">22536333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas P, Ram&#xed;rez AI, Fern&#xe1;ndez-Albarral JA, et al. Amyotrophic lateral sclerosis: a neurodegenerative motor neuron disease with ocular involvement. Front Neurosci. 2020 doi: 10.3389/fnins.2020.566858.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.566858</ArticleId><ArticleId IdType="pmc">PMC7544921</ArticleId><ArticleId IdType="pubmed">33071739</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldatov VO, Kukharsky MS, Belykh AE, et al. Retinal damage in amyotrophic lateral sclerosis: underlying mechanisms. Eye Brain. 2021;13:131&#x2013;146. doi: 10.2147/EB.S299423.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/EB.S299423</ArticleId><ArticleId IdType="pmc">PMC8128130</ArticleId><ArticleId IdType="pubmed">34012311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringelstein M, Albrecht P, S&#xfc;dmeyer M, et al. Subtle retinal pathology in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014;1:290&#x2013;297. doi: 10.1002/acn3.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.46</ArticleId><ArticleId IdType="pmc">PMC4292746</ArticleId><ArticleId IdType="pubmed">25590041</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth NM, Saidha S, Zimmermann H, et al. Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20:1170&#x2013;1176. doi: 10.1111/ene.12146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12146</ArticleId><ArticleId IdType="pubmed">23582075</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonett JM, Huang R, Siddique N, et al. Macular sub-layer thinning and association with pulmonary function tests in amyotrophic lateral sclerosis. Sci Rep. 2016;6:29187. doi: 10.1038/srep29187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep29187</ArticleId><ArticleId IdType="pmc">PMC4935870</ArticleId><ArticleId IdType="pubmed">27383525</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas P, de Hoz R, Ram&#xed;rez A, et al. Changes in retinal OCT and their correlations with neurological disability in early ALS patients, a follow-up study. Brain Sci. 2019;9:337. doi: 10.3390/brainsci9120337.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci9120337</ArticleId><ArticleId IdType="pmc">PMC6955774</ArticleId><ArticleId IdType="pubmed">31771268</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpe NJ, Simonett J, Fawzi AA, Siddique T. Ophthalmic manifestations of amyotrophic lateral sclerosis (An American Ophthalmological Society Thesis) Trans Am Ophthalmol Soc. 2015;113:T12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731009</ArticleId><ArticleId IdType="pubmed">26877563</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeraja K, Nalini A, Preethish-Kumar V, et al. S160. Retinal involvement by optical coherence tomography and its correlation with disease severity in amyotrophic lateral sclerosis. Clin Neurophysiol. 2018;129:e201. doi: 10.1016/j.clinph.2018.04.520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.04.520</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli EG, Agosta F, Ferraro PM, et al. Brain MRI shows white matter sparing in Kennedy&#x2019;s disease and slow-progressing lower motor neuron disease. Hum Brain Mapp. 2019 doi: 10.1002/hbm.24583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24583</ArticleId><ArticleId IdType="pmc">PMC6865482</ArticleId><ArticleId IdType="pubmed">30924230</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Scorza FA. Central nervous system abnormalities in spinal and bulbar muscular atrophy (Kennedy&#x2019;s disease) Clin Neurol Neurosurg. 2019;184:105426. doi: 10.1016/j.clineuro.2019.105426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2019.105426</ArticleId><ArticleId IdType="pubmed">31351215</ArticleId></ArticleIdList></Reference><Reference><Citation>Unrath A, M&#xfc;ller H-P, Riecker A, et al. Whole brain-based analysis of regional white matter tract alterations in rare motor neuron diseases by diffusion tensor imaging. Hum Brain Mapp NA-NA. 2010 doi: 10.1002/hbm.20971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20971</ArticleId><ArticleId IdType="pmc">PMC6871219</ArticleId><ArticleId IdType="pubmed">20336652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, Juengling FD, Sperfeld A-D. Widespread white matter changes in Kennedy disease: a voxel based morphometry study. J Neurol Neurosurg Psychiatry. 2007;78:1209&#x2013;1212. doi: 10.1136/jnnp.2006.112532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.112532</ArticleId><ArticleId IdType="pmc">PMC2117581</ArticleId><ArticleId IdType="pubmed">17332050</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>